Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Bryan Bridgeman"'
Autor:
Greg Malnassy, Claudia R. Keating, Shaimaa Gad, Bryan Bridgeman, Aldeb Perera, Wei Hou, Scott J. Cotler, Xianzhong Ding, Mashkoor Choudhry, Zhaoli Sun, Anthony J. Koleske, Wei Qiu
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 16, Iss 5, Pp 685-709 (2023)
Background & Aims: Alcohol-associated liver disease (ALD) represents a spectrum of alcohol use-related liver diseases. Outside of alcohol abstinence, there are currently no Food and Drug Administration–approved treatments for advanced ALD, necessit
Externí odkaz:
https://doaj.org/article/5f68821b84b34b34841dd8c2d00f4bab
Autor:
Wei Hou, Bryan Bridgeman, Greg Malnassy, Xianzhong Ding, Scott J. Cotler, Asha Dhanarajan, Wei Qiu
Publikováno v:
Hepatology Communications, Vol 6, Iss 7, Pp 1786-1802 (2022)
Abstract Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the underlying mechanisms governing this resistance are largely
Externí odkaz:
https://doaj.org/article/16310e177c80497aa4238e32d1c19f13
Autor:
Abdul S. Qadir, Jean Philippe Guégan, Christophe Ginestier, Assia Chaibi, Alban Bessede, Emmanuelle Charafe-Jauffret, Manon Macario, Vincent Lavoué, Thibault de la Motte Rouge, Calvin Law, Jacob Vilker, Hongbin Wang, Emily Stroup, Matthew J. Schipma, Bryan Bridgeman, Andrea E. Murmann, Zhe Ji, Patrick Legembre, Marcus E. Peter
Publikováno v:
iScience, Vol 24, Iss 11, Pp 103348- (2021)
Summary: The apoptosis inducing receptor CD95/Fas has multiple tumorigenic activities. In different genetically engineered mouse models tumor-expressed CD95 was shown to be critical for cell growth. Using a combination of immune-deficient and immune-
Externí odkaz:
https://doaj.org/article/01c1b9341da244a5b4a9946be1c614bf